Products
Online Inquiry
ENPP1 Blocking Peptide (C-KTHLPTFSQED)
Cat. No.:
OB0526-WX34
Origin:
Synthetic
Conjugation:
Unconjugate
Species Reactivity:
Human; Mouse; Rat
Size:
Add to basket
Product Overview
Description:
ENPP1 Blocking Peptide (C-KTHLPTFSQED) is a highly purified synthetic peptide matching the immunizing epitope of selected ENPP1 antibodies. It is designed to competitively inhibit antibody binding and facilitate confirmation of target-specific signal detection. This reagent provides an effective control for validating ENPP1 immunoassay results.
Sequence:
C-KTHLPTFSQED
Molecular Weight:
1421.5 Da
Purity:
≥95%
Applications:
Western blotting; ELISA; IHC; IF; Functional Assay; Cell Culture; Binding Assay
Specification
Storage:
Storage at -20°C.
Shipping Condition:
Shipped with ice packs.
Handling Notes:
During shipping, trace amounts of the blocking peptide may adhere to the interior surface of the vial cap. Before opening, it is highly recommended to briefly centrifuge the vial to bring all contents to the bottom.
Target Profile
Full Name:
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
Alternative Names:
ENPP1; Ectonucleotide Pyrophosphatase/Phosphodiesterase 1; E-NPP 1; Alkaline phosphodiesterase I; Membrane component chromosome 6 surface marker 1; Nucleotide diphosphatase; Nucleotide pyrophosphatase; Phosphodiesterase I/nucleotide pyrophosphatase 1; Plasma-cell membrane glycoprotein PC-1; M6S1; NPPS; PC1; PDNP1
Summary:
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) is a type II transmembrane glycoprotein that forms a disulfide-linked homodimer and belongs to the ENPP enzyme family. It hydrolyzes a range of substrates containing phosphodiester or pyrophosphate bonds, including nucleotides and nucleotide sugars. ENPP1 can convert nucleoside triphosphates into their corresponding monophosphates and may also act on diadenosine polyphosphates. Genetic variants in ENPP1 have been associated with idiopathic infantile arterial calcification, ossification of the posterior longitudinal ligament of the spine, and insulin resistance.
